File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.12809/hkjr1716810
- Scopus: eid_2-s2.0-85041482379
- WOS: WOS:000436691500009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: S-1 Versus S-1 Plus Cisplatin as First-line Treatment for Metastatic Gastric Cancer
Title | S-1 Versus S-1 Plus Cisplatin as First-line Treatment for Metastatic Gastric Cancer |
---|---|
Authors | |
Keywords | Cisplatin Neoplasm metastasis S-1 (combination) Stomach neoplasms |
Issue Date | 2017 |
Publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.org |
Citation | Hong Kong Journal of Radiology, 2017, v. 20, p. 318-322 How to Cite? |
Abstract | Objective: To compare S-1 with S-1 plus cisplatin (SP) as first-line treatment for metastatic gastric cancer.
Methods: Records of patients with metastatic gastric cancer who received either the S-1 or SP regimen as first-line treatment for metastatic gastric cancer between January 2013 and December 2014 in Queen Mary Hospital were retrospectively reviewed. Baseline characteristics, overall response rate, median progression-free survival (PFS), overall survival (OS), and toxicity of the two groups were compared.
Results: During the study period, 17 patients received S-1 and 13 patients received SP. The median patient ages were 69 and 57 years, respectively. In the S-1 group, more patients were aged ≥70 years (47.1% vs. 7.7%, p = 0.02), fewer patients underwent surgical resection of primary tumours (23.5% vs. 53.8%, p = 0.09), more patients required initial dose reduction (70.6% vs. 15.4%, p = 0.001), and fewer patients received subsequent chemotherapy (5.9% vs. 30.8%, p = 0.07) compared with the SP group. The S-1 group had a lower response rate (11.8% vs. 46.2%, p = 0.049). Nonetheless, S-1 and SP groups were comparable for clinical benefit rate (47.1% vs. 77.0%, p = 0.14), median PFS (34.5 weeks vs. 28.8 weeks, p = 0.72), median OS (46.4 weeks vs. 52.7 weeks, p = 0.18), and 30-day mortality (11.8% vs. 7.7%, p = 1.00). There was a trend of improved OS in the SP group (hazard ratio = 1.84, 95% confidence interval = 0.74-4.55, p = 0.185). The two groups were also comparable for the rate of grade 3/4 neutropaenia (17.7% vs. 38.5%, p = 0.24) and grade 3/4 diarrhoea (5.9% vs. 30.8%, p = 0.14). There was no treatment-related death.
Conclusion: Both S-1 and SP regimens are effective and safe as first-line treatment for metastatic gastric cancer. A dose-adjusted S-1 regimen is a viable option for patients with advanced age and marginal performance status. |
Persistent Identifier | http://hdl.handle.net/10722/258364 |
ISSN | 2023 Impact Factor: 0.2 2023 SCImago Journal Rankings: 0.127 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lau, KS | - |
dc.contributor.author | Lam, KO | - |
dc.contributor.author | Chan, WLW | - |
dc.contributor.author | Lee, VHF | - |
dc.contributor.author | Kwong, DLW | - |
dc.contributor.author | Leung, TW | - |
dc.date.accessioned | 2018-08-22T01:37:18Z | - |
dc.date.available | 2018-08-22T01:37:18Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Hong Kong Journal of Radiology, 2017, v. 20, p. 318-322 | - |
dc.identifier.issn | 2223-6619 | - |
dc.identifier.uri | http://hdl.handle.net/10722/258364 | - |
dc.description.abstract | Objective: To compare S-1 with S-1 plus cisplatin (SP) as first-line treatment for metastatic gastric cancer. Methods: Records of patients with metastatic gastric cancer who received either the S-1 or SP regimen as first-line treatment for metastatic gastric cancer between January 2013 and December 2014 in Queen Mary Hospital were retrospectively reviewed. Baseline characteristics, overall response rate, median progression-free survival (PFS), overall survival (OS), and toxicity of the two groups were compared. Results: During the study period, 17 patients received S-1 and 13 patients received SP. The median patient ages were 69 and 57 years, respectively. In the S-1 group, more patients were aged ≥70 years (47.1% vs. 7.7%, p = 0.02), fewer patients underwent surgical resection of primary tumours (23.5% vs. 53.8%, p = 0.09), more patients required initial dose reduction (70.6% vs. 15.4%, p = 0.001), and fewer patients received subsequent chemotherapy (5.9% vs. 30.8%, p = 0.07) compared with the SP group. The S-1 group had a lower response rate (11.8% vs. 46.2%, p = 0.049). Nonetheless, S-1 and SP groups were comparable for clinical benefit rate (47.1% vs. 77.0%, p = 0.14), median PFS (34.5 weeks vs. 28.8 weeks, p = 0.72), median OS (46.4 weeks vs. 52.7 weeks, p = 0.18), and 30-day mortality (11.8% vs. 7.7%, p = 1.00). There was a trend of improved OS in the SP group (hazard ratio = 1.84, 95% confidence interval = 0.74-4.55, p = 0.185). The two groups were also comparable for the rate of grade 3/4 neutropaenia (17.7% vs. 38.5%, p = 0.24) and grade 3/4 diarrhoea (5.9% vs. 30.8%, p = 0.14). There was no treatment-related death. Conclusion: Both S-1 and SP regimens are effective and safe as first-line treatment for metastatic gastric cancer. A dose-adjusted S-1 regimen is a viable option for patients with advanced age and marginal performance status. | - |
dc.language | eng | - |
dc.publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.org | - |
dc.relation.ispartof | Hong Kong Journal of Radiology | - |
dc.relation.ispartof | 香港放射科醫學雜誌 | - |
dc.rights | Hong Kong Journal of Radiology. Copyright © Hong Kong Academy of Medicine Press. | - |
dc.subject | Cisplatin | - |
dc.subject | Neoplasm metastasis | - |
dc.subject | S-1 (combination) | - |
dc.subject | Stomach neoplasms | - |
dc.title | S-1 Versus S-1 Plus Cisplatin as First-line Treatment for Metastatic Gastric Cancer | - |
dc.type | Article | - |
dc.identifier.email | Lau, KS: lauks18@hku.hk | - |
dc.identifier.email | Lam, KO: lamkaon@hku.hk | - |
dc.identifier.email | Chan, WLW: winglok@hku.hk | - |
dc.identifier.email | Lee, VHF: vhflee@hku.hk | - |
dc.identifier.email | Kwong, DLW: dlwkwong@hku.hk | - |
dc.identifier.email | Leung, TW: ltw920@hkucc.hku.hk | - |
dc.identifier.authority | Lam, KO=rp01501 | - |
dc.identifier.authority | Chan, WLW=rp02541 | - |
dc.identifier.authority | Lee, VHF=rp00264 | - |
dc.identifier.authority | Kwong, DLW=rp00414 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.12809/hkjr1716810 | - |
dc.identifier.scopus | eid_2-s2.0-85041482379 | - |
dc.identifier.hkuros | 286429 | - |
dc.identifier.hkuros | 276599 | - |
dc.identifier.volume | 20 | - |
dc.identifier.spage | 318 | - |
dc.identifier.epage | 322 | - |
dc.identifier.isi | WOS:000436691500009 | - |
dc.publisher.place | Hong Kong | - |
dc.identifier.issnl | 2223-6619 | - |